Holen Sie sich die Stockscreener-App
4.97
0.82%
0.08
Handel nachbörslich:
4.75
-0.22
-4.43%
Schlusskurs vom Vortag:
$4.89
Offen:
$4.83
24-Stunden-Volumen:
68,524
Relative Volume:
0.56
Marktkapitalisierung:
$15.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-1.5292
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
-3.90%
1M Leistung:
-2.95%
6M Leistung:
+1,574%
1J Leistung:
+137.02%
1-Tages-Spanne:
$4.70
$4.97
1-Wochen-Bereich:
$4.56
$5.1893
52-Wochen-Spanne:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Vergleichen Sie CLRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.97 | 15.61M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Cellectar (CLRB) Unveils Promising Preclinical Results for CLR 2 - GuruFocus
Cellectar’s experimental cancer drug shows promise in pancreatic models - Investing.com India
Cellectar’s experimental cancer drug shows promise in pancreatic models By Investing.com - Investing.com Australia
Cellectar Biosciences Presented Promising Preclinical Data - GlobeNewswire
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research - Stock Titan
What technical models suggest about Cellectar Biosciences Inc.’s comebackWeekly Profit Summary & Daily Risk Controlled Trade Plans - newser.com
Is Cellectar Biosciences Inc. stock a safe investment in uncertain marketsMarket Weekly Review & Verified Swing Trading Watchlist - newser.com
Will Cellectar Biosciences Inc. stock pay special dividendsPortfolio Growth Summary & Real-Time Sentiment Analysis - newser.com
Can Cellectar Biosciences Inc. rally from current levels2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Is Cellectar Biosciences Inc. forming a bottoming baseJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Cellectar Biosciences Inc. stock a bargain at current levelsIndex Update & AI Driven Stock Movement Reports - newser.com
How to track smart money flows in Cellectar Biosciences Inc.Market Movement Recap & High Accuracy Buy Signal Tips - newser.com
Is Cellectar Biosciences Inc. stock a buy in volatile markets2025 Major Catalysts & Fast Gain Stock Tips - newser.com
Using Python tools to backtest Cellectar Biosciences Inc. strategiesIPO Watch & Long-Term Investment Growth Plans - newser.com
How analysts rate Cellectar Biosciences Inc. stock todayWeekly Trend Recap & Consistent Profit Alerts - newser.com
Predicting Cellectar Biosciences Inc. trend using moving averagesSell Signal & Daily Growth Stock Investment Tips - newser.com
Is Cellectar Biosciences Inc. meeting your algorithmic filter criteriaEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
What drives Cellectar Biosciences Inc stock priceLow Risk Investment Ideas & Free Record-Breaking Gains - earlytimes.in
Cellectar Biosciences Raises $5.8M Through Warrant Exercise - MSN
Cellectar Biosciences raises $5.8 million through warrant exercise and new inducement warrants - Investing.com Canada
Will Cellectar Biosciences Inc. price bounce be sustainable2025 Top Decliners & Daily Profit Focused Screening - newser.com
Understanding Cellectar Biosciences Inc.’s price movementWeekly Investment Summary & AI Forecasted Entry and Exit Points - newser.com
Cellectar Biosciences Inc. stock prediction for this weekMarket Rally & Low Drawdown Investment Ideas - newser.com
Custom watchlist performance reports with Cellectar Biosciences Inc.CPI Data & Long-Term Growth Plans - newser.com
Analyzing net buyer seller activity in Cellectar Biosciences Inc.Quarterly Portfolio Report & Safe Investment Capital Preservation Plans - newser.com
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences (CLRB) Secures $5.8 Million Through Warran - GuruFocus
Cellectar Biosciences raises $5.8 million through warrant exercise - Investing.com
Cellectar Biosciences enters agreements to raise $5.8M - TipRanks
Cellectar Biosciences raises $5.8 million through warrant exercise By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. enters into agreements to raise $5.8 million - MarketScreener
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million - GlobeNewswire
Cellectar’s cancer drug advances toward European approval By Investing.com - Investing.com Nigeria
Cellectar Biosciences Announces European Medicines Agency - GlobeNewswire
Cellectar Biosciences (CLRB) Receives Positive Feedback for EU M - GuruFocus
What margin trends mean for Cellectar Biosciences Inc. stockEarnings Recap Summary & Growth Focused Stock Pick Reports - newser.com
Cellectar’s cancer drug advances toward European approval - Investing.com
Cellectar Biosciences Stock Rises Over EMA's Advise On CMA Filing For Iopofosine I 131 - Nasdaq
Cellectar Biosciences (CLRB) Moves Toward European Market with Potential Cancer Treatment - GuruFocus
Cellectar wins EMA nod to seek conditional approval for iopofosine in rare blood cancer - MarketScreener
Cellectar Biosciences Plans Conditional Marketing Authorization Submission for Iopofosine I 131 as Treatment for Refractory Waldenstrom Macroglobulinemia in Europe by Early 2026 - Quiver Quantitative
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) - The Manila Times
Cellectar Biosciences Announces Iopofosine I 131 as A Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm) - MarketScreener
Is Cellectar Biosciences Inc. stock a safe haven assetSell Signal & Long-Term Safe Investment Ideas - newser.com
83.6% ORR — Cellectar's Iopofosine I‑131 Eligible to File with EMA for CMA, Aiming for EU Approval - Stock Titan
How Cellectar Biosciences Inc. stock benefits from tech adoption2025 Market Overview & Real-Time Volume Analysis - newser.com
How to forecast Cellectar Biosciences Inc. trends using time series2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Can Cellectar Biosciences Inc. (NV4) stock hold up in economic slowdownTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cellectar Biosciences Inc-Aktie (CLRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):